Tirzepatide 5mg Weight Loss: What Happens at the Second Dose Level

What the SURMOUNT-1 trial tells us about dose and weight loss

The clearest evidence for tirzepatide across its dose range comes from SURMOUNT-1, published in the New England Journal of Medicine, which randomised 2,539 adults with obesity but without type 2 diabetes to one of three active doses or placebo over 72 weeks. The 5mg arm produced an average body-weight reduction of around 15% from baseline, roughly three times what the placebo group achieved. That figure sat between the results for 10mg, which produced around 19.5% weight loss, and the higher end at 15mg (around 20–21%), which tells you two things: the dose-response relationship in tirzepatide is real, and 5mg already represents a substantial clinical effect for many people.

NICE reviewed this evidence when it recommended tirzepatide in December 2024 (TA1026), concluding that the medicine offers a clinically meaningful reduction in body weight for adults who meet the eligibility criteria. The trial's design is worth noting: participants combined treatment with a reduced-calorie diet and increased physical activity, which is how tirzepatide is licensed to be used.

For many people, 5mg is a transitional dose on the way to a higher maintenance level. For others, particularly those who find the GI effects noticeable, a prescriber may decide to extend time at 5mg before moving further. That is a clinical call made on evidence, your prescriber's, not this page's.

Why 5mg follows 2.5mg, and when it might stay longer than expected

The 2.5mg dose that opens the tirzepatide schedule is not intended to produce significant weight loss. Its job is to settle your system, reducing the likelihood of severe nausea or vomiting as your gut adjusts to a medicine that slows gastric emptying and changes how hunger signals are processed. The step to 5mg typically comes after four weeks, and it is the point at which many people notice appetite suppression becoming noticeably stronger.

The NHS tirzepatide page describes the licensed UK dose schedule and notes that titration timing is guided by tolerability. If someone is still managing significant nausea at 2.5mg, staying there a little longer before moving to 5mg is reasonable, and vice versa, if 5mg is well tolerated, the next review will consider whether 7.5mg is the right step. You can read more about where that next step leads on our tirzepatide 7.5mg page.

One thing worth knowing: the pen in the fridge holds four weekly doses, so each prescription covers one full month. The 5mg pen is a distinct product from the 2.5mg starter pen, and your prescriber will specify which to use. Pen stays in the fridge door between uses, the SmPC sets out the exact room-temperature window if you ever need it while travelling.

Side effects at 5mg: what changes when you step up

GI side effects are the most common reason people pause or extend time at a given dose. At 5mg, the most frequently reported are nausea, loose stools, reduced appetite (which is partly the mechanism, partly uncomfortable at first), and occasional indigestion. These tend to peak in the first week or two after increasing and settle as the body adjusts, the pattern generally mirrors what happened at 2.5mg, but can feel more noticeable because the effect is stronger.

Staying well hydrated matters. If vomiting or diarrhoea is prolonged, it can affect how other medicines are absorbed, which is why the prescriber-patient conversation after each dose step is clinically useful rather than optional. Our FAQs page covers questions about managing side effects in more detail.

The January 2026 MHRA Drug Safety Update flagged acute pancreatitis as an infrequent but serious known risk across GLP-1 medicines: severe stomach pain that radiates to the back, with or without vomiting, warrants urgent medical attention rather than waiting it out. Report any suspected side effect via the MHRA Yellow Card scheme, the system is open to patients directly, not just clinicians.

Who reaches 5mg, and how a prescriber decides what comes next

Most people prescribed Mounjaro for weight management will pass through 5mg on the way to a higher dose. The licensed range runs up to 15mg, and the overall picture of how the doses compare is laid out on our tirzepatide doses for weight loss page. Whether someone remains at 5mg as a maintenance dose or moves on depends on how much weight has been lost, how well the dose is tolerated, and what the prescriber judges to be clinically appropriate.

Private eligibility follows the licensed criteria: adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, type 2 diabetes, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. A BMI figure alone never confirms suitability, the full clinical picture does. If you are thinking about how the cost of ongoing treatment fits into a longer plan, the cost context page explains what private pricing typically includes and why the cheapest listing is rarely the right yardstick for a prescription medicine.

For a broader view of the tirzepatide programme and how the service works, our Mounjaro overview covers the ground. And if you are ready to talk to a prescriber about whether this is the right step for you, that conversation starts at our free consultation.